Dr. Garry Morefield has been the President at VaxForm, LLC for 10 years. Prior to founding VaxForm, Dr. Morefield was the head of formulation and stability at Sanofi Pasteur. At Sanofi Pasteur he worked on a variety of bacterial and viral vaccine targets from pre-clinical development through clinical phases as well as marketed products. These included seasonal and pandemic influenza, pneumococcal and meningococcal conjugates, meningococcal group B, C. difficile, hepatitis B, inactivated polio, diphtheria, tetanus, pertussis as well as combination vaccine products. Dr. Morefield has additional experience with biodefense vaccine development while working at the United States Army Medical Research Institute of Infectious Disease. While there he participated in formulation development of Streptococcal enterotoxin B, anthrax, plague, and botulinum neurotoxin A vaccines. Additionally, he has particular expertise in adjuvant development and production including TLR and CTL agonists, squalene-based emulsions, and aluminum salts. Dr. Morefield is a recognized expert in aluminum adjuvants giving multiple talks at research conferences, private company workshops, and as an expert witness in patent prosecutions.
Deputy Director, Process Development
Dr. Elodie Burlet was the lead scientist at VaxForm for 5 years before being promoted to Deputy Director of Process Development. She was the technical lead on the SBIR Phase I NSF-funded project to develop an oral DTaP vaccine and the main scientist in charge of VaxForm’s STTR phase II project to develop a vaccine against Group A Streptococcus. She has 6 years of experience in pre-clinical vaccine formulation and development. Dr. Burlet has worked on a variety vaccine development projects, including Group A Streptococcus, Staphylococcus Aureus, inactivated rabies, pneumococcal conjugates, as well as combination vaccine products. She has particular expertise in biophysical characterization, E.Coli fermentation, tangential flow filtration, analytical assays development, aluminum adjuvant production, and small-scale vaccine manufacturing and filling. Dr. Burlet will serve as the principal investigator for this SBIR Phase I project.